- Home
- MOH vs MRNA Comparison
MOH vs MRNA Comparison
Compare MOH & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOH
- MRNA
- Stock Information
- Founded
- MOH 1980
- MRNA 2010
- Country
- MOH United States
- MRNA United States
- Employees
- MOH N/A
- MRNA N/A
- Industry
- MOH Medical Specialities
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOH Health Care
- MRNA Health Care
- Exchange
- MOH Nasdaq
- MRNA Nasdaq
- Market Cap
- MOH 10.5B
- MRNA 9.8B
- IPO Year
- MOH 2003
- MRNA 2018
- Fundamental
- Price
- MOH $156.00
- MRNA $24.52
- Analyst Decision
- MOH Hold
- MRNA Hold
- Analyst Count
- MOH 13
- MRNA 15
- Target Price
- MOH $211.17
- MRNA $37.15
- AVG Volume (30 Days)
- MOH 1.7M
- MRNA 8.5M
- Earning Date
- MOH 10-22-2025
- MRNA 11-06-2025
- Dividend Yield
- MOH N/A
- MRNA N/A
- EPS Growth
- MOH N/A
- MRNA N/A
- EPS
- MOH 16.24
- MRNA N/A
- Revenue
- MOH $42,842,000,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- MOH $14.48
- MRNA N/A
- Revenue Next Year
- MOH $6.17
- MRNA $11.12
- P/E Ratio
- MOH $9.87
- MRNA N/A
- Revenue Growth
- MOH 14.11
- MRNA N/A
- 52 Week Low
- MOH $151.95
- MRNA $23.15
- 52 Week High
- MOH $359.97
- MRNA $57.69
- Technical
- Relative Strength Index (RSI)
- MOH 28.98
- MRNA 39.59
- Support Level
- MOH $152.25
- MRNA $25.57
- Resistance Level
- MOH $166.31
- MRNA $27.37
- Average True Range (ATR)
- MOH 5.91
- MRNA 1.14
- MACD
- MOH -4.60
- MRNA -0.32
- Stochastic Oscillator
- MOH 7.98
- MRNA 6.38
About MOH Molina Healthcare Inc
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.